Grifols, S.A. (NASDAQ:GRFS - Get Free Report) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,130,000 shares, a drop of 10.8% from the January 15th total of 3,510,000 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 3.0 days.
Hedge funds have recently bought and sold shares of the stock. R Squared Ltd purchased a new stake in shares of Grifols during the 4th quarter valued at $28,000. GAMMA Investing LLC lifted its stake in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC lifted its stake in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 2,153 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 4,970 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 6,335 shares during the last quarter.
Shares of GRFS traded up $0.06 during trading hours on Tuesday, reaching $7.38. 890,787 shares of the company's stock traded hands, compared to its average volume of 787,151. Grifols has a 12 month low of $5.30 and a 12 month high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm's 50 day simple moving average is $7.38 and its 200-day simple moving average is $8.09.
A number of analysts recently weighed in on GRFS shares. Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. Berenberg Bank upgraded Grifols to a "strong-buy" rating in a research report on Tuesday, October 29th.
Read Our Latest Analysis on GRFS
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.